Lung-retentive liposomes via monocyte recruitment for the treatment of acute respiratory distress syndrome
Journal of Controlled Release · 2026-11 · 399 · 115307
DOI: 10.1016/j.jconrel.2026.115307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Hao Tian und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China; School of Pharmacy, Qingdao University, Qingdao 266071, …. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Monocytes, Anti-Inflammatory Agents, Lung. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory disease with a high mortality rate. Conventional in vivo monocyte-targeted strategies are fundamentally limited by the low physiological abundance of circulating monocytes, which represents a major unmet technical barrier on delivery efficiency. Herein, we report an organ-to-cell cascade-targeting strategy that overcomes this long-standing barrier via in situ monocyte recruitment in the pulmonary microvasculature. Herein, we engineered mMP-DDAB, a methylprednisolone (MPS)-loaded liposome co-modified with the lung-targeting functional lipid and CCR2-binding peptide. By virtue of DDAB-mediated lung retention and MP-triggered chemotaxis, mMP-DDAB first accumulates in the pulmonary microvasculature, then actively recruits monocytes, achieving an organ-to-cell cascade-targeting delivery. Following monocyte-targeted delivery and sustained MPS release, mMP-DDAB exerted potent anti-inflammatory and pro-resolving effects in the LPS-induced ARDS mouse model, as evidenced by reduced BALF neutrophil infiltration and protein leakage, suppressed pro-inflammatory cytokines, modulated the pulmonary monocyte/macrophage activation profile toward a more pro-resolving state, and mitigated histopathological lung injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China; School of Pharmacy, Qingdao University, Qingdao 266071, China.
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China.
- Department of Pharmacy, Air Force Medical Center, PLA, Air Force Medical University, Beijing 100142, China.
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China; School of Pharmacy, Guangxi Medical University, Nanning 530021, China.
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
- State Key Laboratory of National Security Specially Needed Medicines, Beijing 100850, China; College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Zitieren
APA
Tian, H., Yao, J., Zhu, Y., Kong, Y., Xu, Z., Yin, S., Meng, Y., Ba, Q., Jia, Y., Wang, Y., Yang, Y., Gao, C., Yuan, H., & Yang, M. (2026). Lung-retentive liposomes via monocyte recruitment for the treatment of acute respiratory distress syndrome. Journal of Controlled Release, 399, 115307. https://doi.org/10.1016/j.jconrel.2026.115307
Vancouver
Tian H, Yao J, Zhu Y, Kong Y, Xu Z, Yin S, et al. Lung-retentive liposomes via monocyte recruitment for the treatment of acute respiratory distress syndrome. Journal of Controlled Release. 2026;399:115307. doi:10.1016/j.jconrel.2026.115307
BibTeX
@article{Tian2026,
author = {Tian, Hao and Yao, Jiaxin and Zhu, Yuwen and Kong, Yichen and Xu, Zhangshen and Yin, Shuhang and Meng, Yuanyuan and Ba, Qi and Jia, Yongbo and Wang, Yuli and Yang, Yang and Gao, Chunsheng and Yuan, Hailong and Yang, Meiyan},
title = {Lung-retentive liposomes via monocyte recruitment for the treatment of acute respiratory distress syndrome},
journal = {Journal of Controlled Release},
year = {2026},
volume = {399},
pages = {115307},
doi = {10.1016/j.jconrel.2026.115307}
}
EUVIMED